EUVIMEDEUVIMED entdecken
Open Access

Detection of HER2-Low Lesions Using HER2-Targeted PET Imaging in Patients with Metastatic Breast Cancer: A Paired HER2 PET and Tumor Biopsy Analysis

Randy Yeh, Fresia Pareja, Parnian Shobeiri, Dara Ross, Vetri S Jayaprakasam, Ali Aria Razmaria, Joshua Z Drago, Audrey Mauguen, Serge K Lyashchenko, Brian M Zeglis, Jason S Lewis, Gary A Ulaner

Journal of Nuclear Medicine · 2025-06 · 66 (6) · 873-879

DOI: 10.2967/jnumed.124.269227 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 08.05.2025. Verfasst von Randy Yeh und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York; yehr@mskcc.org. Hauptthemen laut MEDLINE: Breast Neoplasms, Positron-Emission Tomography, Erb-b2 Receptor Tyrosine Kinases. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Trastuzumab deruxtecan (T-DXd), a human epidermal growth factor receptor 2 (HER2)-targeted antibody-drug conjugate, demonstrated remarkable efficacy in previously treated patients with HER2-low metastatic breast cancer (mBC), marking a new therapeutic option for this patient population. Prior studies with HER2 PET using 89Zr-radiolabeled antibodies were limited by high rates of imaging false positives for HER2-positive malignancy. In this retrospective study, we investigate whether these false positives (HER2-negative on pathology) could be explained by HER2-low lesions.

Methods

A retrospective study was conducted of mBC patients who previously enrolled in 2 prospective HER2 PET imaging trials: NCT02286843 using 89Zr-trastuzumab and 89Zr-pertuzumab and NCT04692831 using 89Zr-ss-pertuzumab. Patients were included if paired HER2 PET scan and biopsy were performed within a 2-mo period. Of 56 total patients, 23 patients met the inclusion criteria. Pathology results for biopsied lesions were collected, without repeat interpretation, and lesions were classified as HER2-positive, HER2-low, or HER2-0. SUVmax of biopsied lesions were compared between pathologic classifications to determine whether lesion uptake intensity could differentiate between HER2-positive and HER2-low lesions.

Results

All prior false-positive lesions on HER2 PET scans from NCT02286843 were reclassified as HER2-low (instead of HER2-negative). In the 89Zr-trastuzumab cohort, 3 lesions were HER2-positive (33%) and 6 were HER2-low (67%); in the 89Zr-pertuzumab cohort, 2 were HER2-positive (29%) and 5 were HER2-low (71%). In the 89Zr-ss-pertuzumab cohort (NCT04692831), 7 patients underwent recent biopsies of 8 total lesions demonstrating 1 HER2-positive (12%), 5 HER2-low (62%), and 2 HER2-0 lesions (25%). HER2 PET SUVmax of biopsied lesions were compared between HER2-positive and HER2-low lesions for the combination of all 3 radiotracer cohorts. HER2-low lesions had a significantly higher SUVmax (median, 12.7; interquartile range, 8.05) than did HER2-positive lesions (median, 6.4; interquartile range, 1.98; P = 0.01).

Conclusion

HER2 PET imaging with 89Zr-radiolabeled antibodies detects HER2-low lesions in addition to HER2-positive lesions in patients with mBC, suggesting its ability to visualize the entire spectrum of HER2 expression. All prior false positives on 89Zr-trastuzumab and 89Zr-pertuzumab PET scans were reclassified as HER2-low. Lesion SUVmax is not reliable in differentiating HER2-positive from HER2-low lesions; however, it may be useful in distinguishing lesions expressing HER2 from HER2-0 lesions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsPositron-Emission TomographyErb-b2 Receptor Tyrosine KinasesAdultAgedFemaleHumansMiddle AgedBiopsyNeoplasm MetastasisRadioisotopesRetrospective StudiesZirconiumClinical Trials, Phase I as TopicMulticenter Studies as Topic

Stichwörter der Autor:innen

HER2PETbreast cancerpathology

Substanzen

RadioisotopesErb-b2 Receptor Tyrosine KinasesZirconiumERBB2 protein, humanZirconium-89

Autor:innen und Institutionen

  • Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York; yehr@mskcc.org.
  • Department of Radiology, Weill Cornell Medical College, New York, New York.
  • Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Department of Pathology, Weill Cornell Medical College, New York, New York.
  • Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.

Förderung

  • NCI NIH HHS

Zitieren

APA

Yeh, R., Pareja, F., Shobeiri, P., Ross, D., Jayaprakasam, V. S., Razmaria, A. A., Drago, J. Z., Mauguen, A., Lyashchenko, S. K., Zeglis, B. M., Lewis, J. S., & Ulaner, G. A. (2025). Detection of HER2-Low Lesions Using HER2-Targeted PET Imaging in Patients with Metastatic Breast Cancer: A Paired HER2 PET and Tumor Biopsy Analysis. Journal of Nuclear Medicine, 66(6), 873-879. https://doi.org/10.2967/jnumed.124.269227

Vancouver

Yeh R, Pareja F, Shobeiri P, Ross D, Jayaprakasam VS, Razmaria AA, et al. Detection of HER2-Low Lesions Using HER2-Targeted PET Imaging in Patients with Metastatic Breast Cancer: A Paired HER2 PET and Tumor Biopsy Analysis. Journal of Nuclear Medicine. 2025;66(6):873-879. doi:10.2967/jnumed.124.269227

BibTeX
@article{Yeh2025,
  author = {Yeh, Randy and Pareja, Fresia and Shobeiri, Parnian and Ross, Dara and Jayaprakasam, Vetri S and Razmaria, Ali Aria and Drago, Joshua Z and Mauguen, Audrey and Lyashchenko, Serge K and Zeglis, Brian M and Lewis, Jason S and Ulaner, Gary A},
  title = {Detection of HER2-Low Lesions Using HER2-Targeted PET Imaging in Patients with Metastatic Breast Cancer: A Paired HER2 PET and Tumor Biopsy Analysis},
  journal = {Journal of Nuclear Medicine},
  year = {2025},
  volume = {66},
  number = {6},
  pages = {873--879},
  doi = {10.2967/jnumed.124.269227}
}
Kostenlos starten →